Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 124

1.

JS-K, a glutathione S-transferase-activated nitric oxide donor with antineoplastic activity in malignant gliomas.

Weyerbrock A, Osterberg N, Psarras N, Baumer B, Kogias E, Werres A, Bette S, Saavedra JE, Keefer LK, Papazoglou A.

Neurosurgery. 2012 Feb;70(2):497-510; discussion 510. doi: 10.1227/NEU.0b013e31823209cf.

2.

Effects of the nitric oxide donor JS-K on the blood-tumor barrier and on orthotopic U87 rat gliomas assessed by MRI.

Weidensteiner C, Reichardt W, Shami PJ, Saavedra JE, Keefer LK, Baumer B, Werres A, Jasinski R, Osterberg N, Weyerbrock A.

Nitric Oxide. 2013 Apr 1;30:17-25. doi: 10.1016/j.niox.2013.01.003. Epub 2013 Jan 28.

3.

JS-K, a glutathione/glutathione S-transferase-activated nitric oxide releasing prodrug inhibits androgen receptor and WNT-signaling in prostate cancer cells.

Laschak M, Spindler KD, Schrader AJ, Hessenauer A, Streicher W, Schrader M, Cronauer MV.

BMC Cancer. 2012 Mar 30;12:130. doi: 10.1186/1471-2407-12-130.

4.

JS-K, a glutathione/glutathione S-transferase-activated nitric oxide donor of the diazeniumdiolate class with potent antineoplastic activity.

Shami PJ, Saavedra JE, Wang LY, Bonifant CL, Diwan BA, Singh SV, Gu Y, Fox SD, Buzard GS, Citro ML, Waterhouse DJ, Davies KM, Ji X, Keefer LK.

Mol Cancer Ther. 2003 Apr;2(4):409-17.

5.

Growth-inhibitory and chemosensitizing effects of the glutathione-S-transferase-π-activated nitric oxide donor PABA/NO in malignant gliomas.

Kogias E, Osterberg N, Baumer B, Psarras N, Koentges C, Papazoglou A, Saavedra JE, Keefer LK, Weyerbrock A.

Int J Cancer. 2012 Mar 1;130(5):1184-94. doi: 10.1002/ijc.26106. Epub 2011 Jul 21.

6.

Nitric oxide-releasing prodrug triggers cancer cell death through deregulation of cellular redox balance.

Maciag AE, Holland RJ, Robert Cheng YS, Rodriguez LG, Saavedra JE, Anderson LM, Keefer LK.

Redox Biol. 2013 Feb 1;1:115-24. doi: 10.1016/j.redox.2012.12.002. eCollection 2013.

7.

Effects of JS-K, a novel anti-cancer nitric oxide prodrug, on gene expression in human hepatoma Hep3B cells.

Dong R, Wang X, Wang H, Liu Z, Liu J, Saavedra JE.

Biomed Pharmacother. 2017 Apr;88:367-373. doi: 10.1016/j.biopha.2017.01.080. Epub 2017 Jan 22.

PMID:
28122301
8.

Synthesis, mechanistic studies, and anti-proliferative activity of glutathione/glutathione S-transferase-activated nitric oxide prodrugs.

Chakrapani H, Kalathur RC, Maciag AE, Citro ML, Ji X, Keefer LK, Saavedra JE.

Bioorg Med Chem. 2008 Nov 15;16(22):9764-71. doi: 10.1016/j.bmc.2008.09.063. Epub 2008 Sep 30.

9.

JS-K has potent anti-angiogenic activity in vitro and inhibits tumour angiogenesis in a multiple myeloma model in vivo.

Kiziltepe T, Anderson KC, Kutok JL, Jia L, Boucher KM, Saavedra JE, Keefer LK, Shami PJ.

J Pharm Pharmacol. 2010 Jan;62(1):145-51. doi: 10.1211/jpp.62.01.0017.

10.

JS-K, a nitric oxide-releasing prodrug, induces breast cancer cell death while sparing normal mammary epithelial cells.

McMurtry V, Saavedra JE, Nieves-Alicea R, Simeone AM, Keefer LK, Tari AM.

Int J Oncol. 2011 Apr;38(4):963-71. doi: 10.3892/ijo.2011.925. Epub 2011 Jan 25.

PMID:
21271218
11.

The nitric oxide prodrug JS-K is effective against non-small-cell lung cancer cells in vitro and in vivo: involvement of reactive oxygen species.

Maciag AE, Chakrapani H, Saavedra JE, Morris NL, Holland RJ, Kosak KM, Shami PJ, Anderson LM, Keefer LK.

J Pharmacol Exp Ther. 2011 Feb;336(2):313-20. doi: 10.1124/jpet.110.174904. Epub 2010 Oct 20.

12.

JS-K, a GST-activated nitric oxide generator, induces DNA double-strand breaks, activates DNA damage response pathways, and induces apoptosis in vitro and in vivo in human multiple myeloma cells.

Kiziltepe T, Hideshima T, Ishitsuka K, Ocio EM, Raje N, Catley L, Li CQ, Trudel LJ, Yasui H, Vallet S, Kutok JL, Chauhan D, Mitsiades CS, Saavedra JE, Wogan GN, Keefer LK, Shami PJ, Anderson KC.

Blood. 2007 Jul 15;110(2):709-18. Epub 2007 Mar 23. Erratum in: Blood. 2007 Dec 15;110(13):4187.

13.
14.

TIMP-2 mediates the anti-invasive effects of the nitric oxide-releasing prodrug JS-K in breast cancer cells.

Simeone AM, McMurtry V, Nieves-Alicea R, Saavedra JE, Keefer LK, Johnson MM, Tari AM.

Breast Cancer Res. 2008;10(3):R44. doi: 10.1186/bcr2095. Epub 2008 May 12.

15.
16.

Nitric oxide prodrug JS-K inhibits ubiquitin E1 and kills tumor cells retaining wild-type p53.

Kitagaki J, Yang Y, Saavedra JE, Colburn NH, Keefer LK, Perantoni AO.

Oncogene. 2009 Jan 29;28(4):619-24. doi: 10.1038/onc.2008.401. Epub 2008 Nov 3.

17.

JS-K, a nitric oxide prodrug, induces cytochrome c release and caspase activation in HL-60 myeloid leukemia cells.

Udupi V, Yu M, Malaviya S, Saavedra JE, Shami PJ.

Leuk Res. 2006 Oct;30(10):1279-83. Epub 2006 Jan 24.

PMID:
16439016
18.

Growth inhibition and chemosensitization of exogenous nitric oxide released from NONOates in glioma cells in vitro.

Weyerbrock A, Baumer B, Papazoglou A.

J Neurosurg. 2009 Jan;110(1):128-36. doi: 10.3171/2008.6.17607.

PMID:
18991497
19.

Cellular distribution studies of the nitric oxide-generating antineoplastic prodrug O(2) -(2,4-dinitrophenyl)1-((4-ethoxycarbonyl)piperazin-1-yl)diazen-1-ium-1,2-diolate formulated in Pluronic P123 micelles.

Kaur I, Terrazas M, Kosak KM, Kern SE, Boucher KM, Shami PJ.

J Pharm Pharmacol. 2013 Sep;65(9):1329-36. doi: 10.1111/jphp.12100. Epub 2013 Jul 10.

20.

Nitric oxide prodrugs and metallochemotherapeutics: JS-K and CB-3-100 enhance arsenic and cisplatin cytolethality by increasing cellular accumulation.

Liu J, Li C, Qu W, Leslie E, Bonifant CL, Buzard GS, Saavedra JE, Keefer LK, Waalkes MP.

Mol Cancer Ther. 2004 Jun;3(6):709-14.

Supplemental Content

Support Center